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Episodic ataxia type 2 (EA-2) is an inherited disorder that is characterized by intermittent vertigo, ataxia, and 
interictal gaze-evoked nystagmus. Although abnormalities associated with this disorder have been found in the 
CACNA1A gene encoding the alpha1A (Cav2.1) subunit of the P/Q-type calcium channel, there are few reports of 
genetically confirmed EA-2 in Korea. In 1998, a Korean family with acetazolamide-responsive hereditary paroxysmal 
ataxia was reported, but the genetic background was not defined at that time. In the present study we performed 
direct sequencing of the entire exons and their flanking intronic sequences of the CACNA1A gene and found a 
deletion mutation (c.2042_2043delAG).
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Several types of channelopathy, including spinocere-
bellar ataxia, familial hemiplegic migraine, and episodic 
ataxia (EA), may manifest with intermittent or progressive 
dizziness and ataxia. EA type 2 (EA-2) is an autosomal 
dominant disorder that is characterized by intermittent 
vertigo, ataxia, and interictal gaze-evoked nystagmus. 
Episodes may develop spontaneously or may be tri-
ggered by stress and exertion. The underlying cause of 
EA-2 is a genetic alteration of the voltage-dependent 
calcium channel (CACNA1A). Acetazolamide markedly 
reduces the number of attacks, possibly by stabilizing 
the ion channels through pH changes in brain tissue.
1 
Previously, one familial case with EA-2 and spino-
cerebellar ataxia type 6 (SCA6) was reported in 
association with CAG repeat expansion, and another 
sporadic case with EA-2 was found to have a balanced 
translocation in CACNA1A.
2,3 However, isolated EA-2 
due to a deletion in CACNA1A has not been 
documented in Korea. In 1998, our group reported on a 
Korean family with acetazolamide-responsive hereditary 
paroxysmal ataxia, but the genetic background was not 
defined at that time.
4 In the present study we direct 
sequenced the entire exons and the flanking intronic 
sequences of the CACNA1A gene, and found a deletion 
mutation (c.2042_2043delAG). Here we report the first 
genetically proven Korean family with EA-2 over three 
generations that is attributable to a deletion in CACNA1A.
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Figure 1. Pedigree of a family with episodic ataxia type 2.
Figure 2. Mutation analysis of the CACNA1A gene. Direct 
sequencing of exon 16 shows overlapped peaks (arrow) from 
nucleotide position 2042 due to a heterozygous 2-base-pair 
deletion (c.2042_2043delAG; p.Gln681ArgfsX16). The proband’s
son and one of his two daughters also had the same mutation.
A 55-year-old man had experienced intermittent 
episodes of ataxia and dysarthria since the age of 15 
years, which were precipitated mostly by emotional 
stress, exertion, exercise, consumption of hot food, and 
hot showers. He reported that the severity and number 
of attacks had increased with age. His past medical 
history was unremarkable. Five of his family members 
had similar symptoms (Fig. 1). Between the attacks, 
physical, neurological, and laboratory findings were 
normal except for subtle gaze-evoked nystagmus. During 
the episodes, he showed aggravated gaze-evoked 
nystagmus, dysarthria, and ataxia involving both arms 
and legs. The episodes lasted 30 min to 1 hour. 
Acetazolamide at 750 mg per day markedly decreased 
the severity and frequency of the episodes. The detailed 
clinical features of this patient and his family members 
have been reported previously.
4
Genetic Analyses
After obtaining their informed consent to participate, 
direct sequencing analysis was applied to three family 
members to detect CACNA1A gene mutations. Genomic 
DNA was extracted from peripheral blood leukocytes 
using the Wizard Genomic DNA Purification Kit 
following the manufacturer’s instructions (Promega, 
Madison, WI, USA). All five coding exons of the 
CACNA1A gene and their flanking intronic regions 
were amplified using primer sets designed by the authors 
(available on request). The polymerase chain reaction15 
was performed with a thermal cycler (model 9700, 
Applied Biosystems, Foster City, CA, USA) as follows: 
initial incubation at 94℃  for 5 min, followed by 32 
cycles of denaturation at 94℃ for 30’s, annealing at 
60℃  for 30’s, and extension at 72℃  for 30’s. The 
amplicon (5μL) was treated with 10 U of shrimp 
alkaline phosphatase and 2 U of exonuclease I (USB, 
Cleveland, OH, USA) at 37℃  for 15 min, and was 
incubated at 80℃ for 15 min for enzyme inactivation. 
Cycle sequencing was performed on an ABI Prism 3100 
Genetic Analyzer with the BigDye Terminator Cycle 
Sequencing Ready Reaction kit (Applied Biosystems).
RESULTS
Direct sequencing of the entire exons and the flanking 
intronic sequences of the CACNA1A gene in the 
proband (II-2; Fig. 2) revealed a heterozygous deletion 
mutation in exon 16 (c.2042_2043delAG base on the 
reference mRNA sequence, NM_000068; Fig. 2), 
resulting in a frameshift in the protein level 
(p.Gln681ArgfsX16). This variation was also found in 
the patient’s affected son and one of his two affected 
daughters. The other family members declined the 
genetic analysis.Journal of Clinical Neurology: Vol. 2, No. 4, 2006
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DISCUSSION
Hereditary EA shows autosomal dominant inheritance. 
In EA type 1 (EA-1), the patient shows paroxysmal 
ataxia with myokymia or myotonia lasting several 
seconds to minutes.
5 Genetic abnormalities include point 
mutations in a potassium channel gene, KCNA1, on 
chromosome 12p.
6 Attacks of EA-2 last longer than 
those of EA-1. EA-2 is associated with mutations in a 
voltage-dependent calcium channel gene, CACNA1A, 
which is located on chromosome 19p and codes for the 
main transmembrane component of a neuronal calcium 
channel.
7 This gene is expressed throughout the nervous 
system, but is especially common in the cerebellum and 
at the neuromuscular junction.
8 Other genetic diseases 
involving CACNA1A include SCA6 and familial 
hemiplegic migraine.
9 The type of mutation is known to 
be only weakly associated with the clinical manifestation 
or severity in EA-2,
10 but CAG repeat expansion is 
found more commonly in SCA6. So far, two genetically 
proven cases of EA-2 have been reported in Korea. The 
first report described a family with EA-2 and SCA6 due 
to CAG repeat expansion in the CACNA1A calcium- 
channel gene.
2 That family comprised both EA-2 and 
SCA6 patients with the same mutation, suggesting that 
SCA6 and EA-2 are allelic disorders. The second report 
was of a 26-year-old man with EA-2 whose genetic 
analysis disclosed reciprocal balanced translocation 
involving CACNA1A.
3 None of his family members had 
EA-2. The patients in our current family had similar 
clinical manifestations as the patients reported pre-
viously; all of them had intermittent episodes of vertigo 
and ataxia, which had started before the age of 20 years. 
The frequency and severity of attacks were attenuated by 
acetazolamide therapy. In our patients, EA-2 was caused 
by a deletion in exon 16 of the CACNA1A gene 
(c.2042,_2043delAG), which has been reported pre-
viously.
11
The unique feature of our patients was that the 
symptoms were induced or aggravated by hot food or a 
hot shower. This is the first description of EA provoked 
by a change in body temperature. Neurological symp-
toms provoked by a rise in the core body temperature 
have been reported in multiple sclerosis as Uhthoff’s 
phenomenon. This rare phenomenon manifests as a 
transient visual loss, motor weakness, or dysphonia 
attributable to a rise in core body temperature. The 
motor weakness associated with Uhthoff’s phenomenon 
has been ascribed to a conduction delay in multiple 
sclerosis patients.
12 There has been a report on 
temporary hearing loss in an otherwise healthy girl 
induced by an increase in her core body temperature.
13 
Auditory brainstem responses revealed an absence of 
neural synchrony during the attack.
13 The symptoms in 
our patients may have been related to a central 
conduction delay induced by a temperature change; 
however, there is currently no known relationship 
between calcium channelopathy and temperature- 
dependent conduction delay. More case reports and 
biochemical studies are needed to elucidate the 
mechanisms underlying this condition.
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